Dementia is a major problem in our aging societies costing nearly a trillion USD worldwide per year. Treatments are on the horizon, but an affordable and widely available diagnostic technique is still missing. Positrigo’s brain Positron Emission Tomography system NeuroLF offers functional brain imaging to everyone at a fraction of today’s cost.
Positrigo is among 37 companies which have been selected to participate in the 2021/2022 IMD Startup Competition. Read more here: IMD selects 37 winners in
The two Swiss based companies Positrigo and Bottneuro have announced a cooperation agreement to foster the early diagnosis and personalized treatment of Alzheimer’s disease. Positrigo,
Positrigo demonstrates commitment to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. Positrigo, a Swiss based company developing nuclear
Our technology was developed at ETH Zurich with support from University of Zurich and University Hospital of Zurich.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements No. 855292 and No. 953844.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements No. 855292 and No. 953844.
ISO 13485:2016
